メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
臨床腫瘍学講座
富山大学
医学系
概要
フィンガープリント
ネットワーク
プロファイル
(2)
プロジェクト
(6)
研究成果
(160)
データセット
(20)
フィンガープリント
臨床腫瘍学講座が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
70%
Advanced Gastric Cancer
70%
Lung Cancer
60%
Chemotherapy
58%
Cisplatin
54%
Progression-free Survival
52%
Irinotecan
47%
Monotherapy
44%
Older Men
37%
Immune Checkpoint Inhibitors
36%
Japan
36%
Overall Survival
36%
Small Cell Lung Cancer
31%
Fluoropyrimidine
30%
Median Progression-free Survival
30%
Docetaxel
29%
Lung Adenocarcinoma
29%
Tumor
29%
Hokushin Region
29%
Gastrointestinal Stromal Tumor
29%
Nivolumab
27%
Multi-institutional Survey
25%
5-fluorouracil (5-FU)
25%
Clinical Course
25%
Median Overall Survival
24%
Lung
23%
Immune Checkpoint Inhibitor Therapy
23%
Human Lung Fibroblasts
22%
Confidence Interval
22%
SRT1720
22%
Combination Chemotherapy
21%
Sirtuin 1 (SIRT1)
20%
Shakuyakukanzoto
20%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
19%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
19%
Cancer Patients
19%
Phase II Study
19%
Adverse Effects
18%
Gastric Cancer
18%
Clinical Outcomes
18%
Metastatic Colorectal Cancer (mCRC)
18%
Endoscopic Submucosal Dissection
18%
Amrubicin
18%
Clinical Practice
18%
Interstitial Pneumonia
17%
Interleukin-6
16%
Oxaliplatin
16%
Prognostic Factors
16%
S-1 Plus Cisplatin
16%
Second-line Chemotherapy
15%
Lung Injury
15%
Multicenter Retrospective Study
15%
Response Rate
15%
Induced Apoptosis
15%
Preventive Effect
15%
First-line Chemotherapy
15%
Computed Tomography
14%
Pembrolizumab
14%
Mikulicz's Disease
14%
Mitomycin C
14%
Eosinophilic Pneumonia
14%
SIRT1 Activator
14%
Intra-aortic Balloon Occlusion
14%
Endoscopic Retrograde Cholangiopancreatography
14%
C-Jun N-terminal Kinase Signaling
14%
Photo-cross-linker
14%
Elderly Patients
14%
Bradykinin
14%
Stomach
14%
Bronchiolitis
14%
Ionizing Radiation
14%
Alveolar Epithelial Cells
14%
Franseen Needle
14%
Interleukin-8
14%
Ulcer
14%
Endoscopic Hemostasis
14%
Liver Metastasis
14%
Clinical Trials
13%
Diarrhea
13%
Epidermal Growth Factor Receptor
13%
Tumor Cells
13%
Multivariate Analysis
13%
Performance Status
13%
Anemia
13%
Adverse Events
12%
Paclitaxel
12%
Pancreas
12%
MRNA Level
12%
Carboplatin
12%
Gastrointestinal Cancer
12%
Lung Cancer Patients
12%
Older Women
12%
UGT1A1
12%
Japanese Patients
12%
Patient Characteristics
12%
Programmed Death-ligand 1 Expression
12%
Retrospective Analysis
12%
Immune-related Adverse Events
11%
Male Patients
11%
Home Death
11%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Abdominal Cancer
75%
Progression Free Survival
74%
Overall Survival
62%
Cisplatin
54%
Non Small Cell Lung Cancer
54%
Retrospective Study
53%
Irinotecan
48%
Adverse Event
47%
Monotherapy
45%
Small Cell Lung Cancer
43%
Immune Checkpoint Inhibitor
39%
Neoplasm
37%
Lung Cancer
36%
Epidermal Growth Factor Receptor
36%
Fluoropyrimidine
30%
Docetaxel
28%
Fluorouracil
23%
Disease
22%
N [2 [3 (1 piperazinylmethyl)imidazo[2,1 B]thiazol 6 Yl]phenyl] 2 Quinoxalinecarboxamide
22%
Oxaliplatin
20%
Messenger RNA
19%
Paclitaxel
18%
Metastatic Colorectal Cancer
18%
Combination Therapy
17%
Nivolumab
17%
Protein P53
16%
Interleukin 6
16%
Programmed Death 1 Ligand 1
16%
Amrubicin
16%
Clinical Trial
16%
Pancreas Cancer
15%
Phosphotransferase
15%
Mitomycin
14%
Ionizing Radiation
14%
Gastrointestinal Stromal Tumor
14%
Neuroendocrine Carcinoma
14%
Imatinib
14%
Bradykinin
14%
Interleukin 8
14%
Recurrent Disease
14%
Diarrhea
14%
First-Line Chemotherapy
14%
Cytokine
13%
Second-Line Chemotherapy
13%
Malignant Neoplasm
13%
Inflammation
13%
Cetuximab
12%
Asthma
12%
Pembrolizumab
12%
Lactate Dehydrogenase
11%
Folinic Acid
11%
Ramucirumab
11%
Neurotoxicity
11%
Disease Course
9%
Gemcitabine
9%
Acute Pancreatitis
9%
Durvalumab
9%
Hydrogen Peroxide
9%
Epidermal Growth Factor Receptor Kinase Inhibitor
9%
Bevacizumab
8%
Colorectal Carcinoma
8%
Liver Metastasis
8%
Inflammatory Bowel Disease
8%
Pancreatitis
8%
Injury
8%
Radiation Pneumonia
8%
Breast Cancer
7%
Carcinoma
7%
Neutropenia
7%
Crohn's Disease
7%
Liver Cell Carcinoma
7%
Glutamate Sodium
7%
Squamous Cell Lung Carcinoma
7%
Immunoglobulin A
7%
Multidrug Resistance Associated Protein 1
7%
Diphtheria Toxin
7%
Infliximab
7%
Mercaptopurine
7%
Chronic Obstructive Lung Disease
7%
Gamma Urogastrone
7%
Pleura Mesothelioma
7%
CagA Protein
7%
Creatinine
7%
Gelatinase A
7%
Fatty Liver
7%
Isoprenaline
7%
Stag
7%
Doxorubicin
7%
Tumor Necrosis Factor Inhibitor
7%
Digestive System Cancer
7%
Legionella
7%
Cystatin C
7%
Vasculitis
7%
Daptomycin
7%
Sunitinib
7%
Colorectal Liver Metastasis
7%
Coumarin
7%
Peritoneum Metastasis
7%
Carnitine
7%
Medicine and Dentistry
Lung Cancer
68%
Chemotherapy
52%
Lung
50%
Non Small Cell Lung Cancer
43%
Abdominal Cancer
42%
Immune Checkpoint Inhibitor
40%
Neoplasm
39%
Progression Free Survival
33%
Retrospective Study
30%
Disease
30%
Lung Adenocarcinoma
29%
Overall Survival
29%
Malignant Neoplasm
28%
Small Cell Lung Cancer
28%
Nivolumab
27%
Computer Assisted Tomography
26%
Disease Course
24%
Arm
21%
Ulcer
21%
Pancreas Cancer
21%
Endoscopic Ultrasound Guided Fine Needle Biopsy
20%
Epidermal Growth Factor Receptor
20%
Endoscopic Submucosal Dissection
18%
Recurrent Disease
17%
Idiopathic Interstitial Pneumonia
17%
Bronchiolitis
17%
Monotherapy
16%
Tumor Cell
15%
Adverse Event
15%
Diagnosis
15%
Metastatic Carcinoma
15%
Löffler's Syndrome
14%
Endoscopic Ultrasound
14%
Fine-Needle Aspiration
14%
Immunoglobulin G4
14%
Mikulicz Disease
14%
Endoscopic Retrograde Cholangiopancreatography
14%
Balloon Occlusion
14%
Endoscopic Hemostasis
14%
Epithelial Cell
14%
Sirtuin1
14%
Prednisolone
14%
Pembrolizumab
14%
Liver Metastasis
13%
Biopsy Technique
12%
Bleeding
12%
Bronchiolitis Obliterans Organizing Pneumonia
12%
Helicobacter Pylori
11%
Patient Characteristics
11%
Immunity
11%
Irinotecan
11%
Gemcitabine
11%
Surgery
11%
Endoscopy
11%
Cisplatin
11%
Evans Syndrome
11%
Small-Cell Carcinoma
11%
Carboplatin
11%
Cancer
10%
Messenger RNA
10%
Dyspnea
10%
T-Helper Cell
10%
Lung Carcinoma
10%
Multivariate Analysis
10%
Thorax Radiography
10%
First-Line Chemotherapy
10%
Prognostic Factor
10%
Adenocarcinoma
9%
Fibrosis
9%
Symptomatic Treatment
9%
Scintigraphy
9%
Protein P53
9%
Duodenum
9%
Combination Chemotherapy
9%
Radiofrequency Ablation
9%
Amino Terminal Sequence
9%
Blood Pressure
9%
Cancer Cell
9%
Immunohistochemistry
9%
Neutrophil
9%
Lymphocyte
9%
Clinical Trial
9%
Systemic Therapy
8%
Loss of Appetite
8%
Immune-Related Adverse Events
8%
Immunoglobulin Producing Cell
8%
Pleura Mesothelioma
8%
Comorbidity
8%
Cellular Infiltration
8%
Ischemic Heart Disease
8%
Provocation Test
8%
Lactate Dehydrogenase
8%
Upregulation
8%
Nonsteroid Antiinflammatory Agent
8%
Radiation Pneumonia
8%
Gefitinib
7%
Meningeal Carcinomatosis
7%
Cancer Staging
7%
Carcinoma
7%
Supportive Care
7%